慢性结肠炎患者穴位敏化表征及分布规律的横断面调查

注册号:

Registration number:

ITMCTR2024000115

最近更新日期:

Date of Last Refreshed on:

2024-07-04

注册时间:

Date of Registration:

2024-07-04

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

慢性结肠炎患者穴位敏化表征及分布规律的横断面调查

Public title:

Cross-sectional investigation of the characterization and distribution pattern of acupoint sensitization in patients with chronic colitis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

慢性结肠炎患者穴位敏化表征及分布规律的横断面调查

Scientific title:

Cross-sectional investigation of the characterization and distribution pattern of acupoint sensitization in patients with chronic colitis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

代表

研究负责人:

乔海法

Applicant:

DAI Biao

Study leader:

QIAO Haifa

申请注册联系人电话:

Applicant telephone:

13183681958

研究负责人电话:

Study leader's telephone:

18220046518

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

412893027@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1511006@sntcm.edu.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

陕西省咸阳市秦都区陕西中医药大学附属医院

研究负责人通讯地址:

陕西省西咸新区西咸大道陕西中医药大学

Applicant address:

Shaanxi xianyang qindu shaanxi university of traditional Chinese medicine hospital

Study leader's address:

Shaanxi University of Traditional Chinese Medicine, Xixian Avenue, Xixian New Area, Shaanxi Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

陕西中医药大学

Applicant's institution:

Shaanxi University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

SZFYIEC-PJ-2024年第[33]号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

陕西中医药大学附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024/3/21 0:00:00

伦理委员会联系人:

钟慧慧

Contact Name of the ethic committee:

ZHONG Huihui

伦理委员会联系地址:

陕西省咸阳市秦都区陕西中医药大学附属医院

Contact Address of the ethic committee:

Shaanxi xianyang qindu shaanxi university of traditional Chinese medicine hospital

伦理委员会联系人电话:

Contact phone of the ethic committee:

029-33377941

伦理委员会联系人邮箱:

Contact email of the ethic committee:

szfyllwyh@163.com

研究实施负责(组长)单位:

陕西中医药大学

Primary sponsor:

Shaanxi University of Chinese Medicine

研究实施负责(组长)单位地址:

陕西省西咸新区西咸大道陕西中医药大学

Primary sponsor's address:

Shaanxi University of Traditional Chinese Medicine, Xixian Avenue, Xixian New Area, Shaanxi Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西

市(区县):

咸阳

Country:

China

Province:

Shaanxi

City:

Xianyang

单位(医院):

陕西中医药大学附属医院

具体地址:

陕西省咸阳市秦都区陕西中医药大学附属医院

Institution
hospital:

Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine

Address:

Shaanxi xianyang qindu shaanxi university of traditional Chinese medicine hospital

经费或物资来源:

国家重点研发计划

Source(s) of funding:

National Key Reaearch Priorities Program of China

研究疾病:

慢性结肠炎

研究疾病代码:

Target disease:

chronic colitis

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

横断面

Cross-sectional

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

通过对慢性结肠炎患者及健康受试者的形敏点、痛敏点和热敏点的探查,总结其敏化表征及分布规律,以期为慢性结肠炎的临床选穴方案的制定与优化提供参考。

Objectives of Study:

By exploring the form-sensitive, pain-sensitive and heat-sensitive points of patients with chronic colitis and healthy subjects, we summarized their sensitization phenotypes and distribution patterns, with a view to providing a reference for the development and optimization of clinical point selection protocols for chronic colitis.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

慢性结肠炎观察组:①符合慢性结肠炎的诊断标准;②性别不限,年龄18-65岁之间;③愿意参与试验并签署知情同意书者。 健康对照组:①无慢性结肠炎及其它消化系统疾病;②性别不限,年龄18-65岁之间;③愿意参与试验并签署知情同意书者。

Inclusion criteria

Chronic colitis observation group:① Meet the diagnostic criteria of chronic colitis;② Sex is not limited, age between 18-65 years old;③ Those who are willing to participate in the trial and sign the informed consent. Healthy control group:① No chronic colitis and other digestive diseases;② Sex is not limited, age between 18-65 years old;③ Those who are willing to participate in the trial and sign the informed consent.

排除标准:

慢性结肠炎观察组:①不符合诊断标准及纳入病例标准者;②既往有心肌梗死、严重心力衰竭、瓣膜性心脏病、严重的心律失常原发性心肌病、血液类疾病以及伴有其他严重脑血管疾病者;③妊娠期、哺乳期妇女及精神类疾病无法配合者;④合并肠结核、细菌性菌痢、恶性肿瘤的患者;⑤具有发热症状影响热敏探查的患者;⑥患有皮肤病影响形敏探查的患者;⑦素有肌骨疾病引起躯体疼痛而影响痛敏探查的患者;⑧同时参加其他临床试验者。 健康对照组:①既往有心肌梗死、严重心力衰竭、瓣膜性心脏病、严重的心律失常原发性心肌病、血液类疾病以及伴有其他严重脑血管疾病者;②妊娠期、哺乳期妇女及精神类疾病无法配合者;③合并肠结核、细菌性菌痢、恶性肿瘤的患者;④具有发热症状影响热敏探查的患者;⑤患有皮肤病影响形敏探查的患者;⑥素有肌骨疾病引起躯体疼痛而影响痛敏探查的患者;⑦同时参加其他临床试验者。

Exclusion criteria:

Chronic colitis observation group: ① does not meet the diagnostic criteria and inclusion criteria; ② previous myocardial infarction, severe heart failure, valvular heart disease, severe arrhythmia primary cardiomyopathy, blood diseases and other serious cerebrovascular disease; ③ pregnancy, breastfeeding women and psychiatric disorders can not be cooperated with; ④ combined with intestinal tuberculosis, bacillary dysentery, malignant tumors; ⑤ with fever symptoms affecting thermal probe; ⑥ patients with skin diseases affecting shape sensitive probe; ⑦ patients with musculoskeletal diseases causing pain and affecting pain sensitive probe; ⑧ also participate in other patients with Patients with fever symptoms affecting the heat sensitivity test; Healthy control group: ① myocardial infarction, severe heart failure, valvular heart disease, severe arrhythmias, primary cardiomyopathy, blood diseases and other serious cerebrovascular disease; ② pregnancy, lactation and mental illness can not cooperate with the patient; ③ combined with intestinal tuberculosis, bacterial dysentery, malignant tumors; ④ with fever symptoms affecting thermal sensitivity test; ⑤ patients with dermatologic diseases affecting shape sensitivity test; ⑥ patients with musculoskeletal diseases causing pain and affecting pain sensitivity test; ⑦ patients who also participate in other clinical trials.

研究实施时间:

Study execute time:

From 2024-03-21

To      2025-03-21

征募观察对象时间:

Recruiting time:

From 2024-03-21

To      2025-03-21

干预措施:

Interventions:

组别:

健康对照组

样本量:

30

Group:

Healthy control group

Sample size:

干预措施:

敏化探查

干预措施代码:

Intervention:

Detection of sensitization

Intervention code:

组别:

慢性结肠炎观察组

样本量:

168

Group:

Chronic colitis observation group

Sample size:

干预措施:

敏化探查

干预措施代码:

Intervention:

Detection of sensitization

Intervention code:

样本总量 Total sample size : 198

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

陕西

市(区县):

咸阳

Country:

China

Province:

Shaanxi

City:

Xianyang

单位(医院):

陕西中医药大学附属医院

单位级别:

三级甲等

Institution/hospital:

Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine

Level of the institution:

Third-class hospital

测量指标:

Outcomes:

指标中文名:

皮肤形态变化

指标类型:

主要指标

Outcome:

Skin morphological changes

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

皮肤温度

指标类型:

主要指标

Outcome:

Skin temperature

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

压痛阈

指标类型:

主要指标

Outcome:

Pressure pain threshold

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 15
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究所用的横斯面调查类型为抽样调查,是指从某个人群总体(即根据研究目的所确定的研究对象的全体)中按照一定原则随机抽取一定数量的有代表性的个体(统计学上称为样本)进行调查,然后用这部分样本的调查结果,推算出人群中某病的患病率或某些特征情况。

Randomization Procedure (please state who generates the random number sequence and by what method):

The type of cross-sectional survey used in this study is a sample survey, which means that a certain number of representative individuals (statistically known as a sample) are randomly selected according to certain principles from the total population of a given population (i.e., the entire population of the study population identified according to the purpose of the study) for the purpose of conducting a survey, and then the results of the survey from this portion of the sample are used to extrapolate the prevalence rate of a certain disease or certain characteristics of a condition in the population.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan临床试验公共管理平台(http://www.medresman.org.cn/uc/index.aspx)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan Clinical Trial Management Public Platform(http://www.medresman.org.cn/uc/index.aspx)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

建立excel数据表,将CRF表上受试者的数据录入,将其作为原始数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

An excel data sheet was created and the subjects' data on the CRF sheet was entered as raw data.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统